Advanced Accelerator Applications SA (AAAP)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Advanced Accelerator Applications SA (AAAP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011881
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Advanced Accelerator Applications SA (AAA) is a healthcare products provider that offers molecular nuclear medicine and diagnostic and therapeutic products. The company’s lead product candidate comprises Lutathera, a lutetium-177 somatostatin analogue peptide that is used for the treatment of midgut neuroendocrine tumors. It provides positron emission tomography and single photon emission computed tomography products. AAA caters to diagnosis in clinical cardiology, oncology, neurology, and infectious and inflammatory diseases. It operates in France, Italy, the UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, the US, and Canada, among others. AAA is headquartered in Saint-Genis-Pouilly, France.

Advanced Accelerator Applications SA (AAAP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Advanced Accelerator Applications SA, Medical Devices Deals, 2011 to YTD 2017 10
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Advanced Accelerator Acquires Rights To Fabovar From Dompe 13
Venture Financing 14
Advanced Accelerator Applications Raises USD26 Million in Venture Financing 14
Advanced Accelerator Applications Raises US$56 Million In Venture Financing 15
Advanced Accelerator Raises US$6 Million In First Tranche Of Venture Financing 16
Advanced Accelerator Secures US$57 Million In Venture Financing 17
Partnerships 18
Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 18
Vect-Horus Enters into Collaboration Agreement with Advanced Accelerator Applications for Radio-Imaging Agents 19
Licensing Agreements 20
Advanced Accelerator Applications Enters into Licensing Agreement with Erasmus University Medical Center and Demokritos National Center 20
Advanced Accelerator Applications Enters into Licensing Agreement with Johns Hopkins University 21
Fujifilm RI Pharma Enters into Licensing Agreement with Advanced Accelerator Applications 22
Equity Offering 23
Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 23
Advanced Accelerator Applications to Raise up to USD80 Million in IPO 25
Acquisition 27
Novartis to Acquire Advanced Accelerator Applications for USD3.9 Billion 27
Advanced Accelerator Applications Acquires IDB Group 29
Advanced Accelerator Applications Acquires Remaining 49.9% Stake in Atreus Pharma 30
Ion Beam Applications Acquires 25% Stake In PET Net 31
Advanced Accelerator Applications SA – Key Competitors 32
Advanced Accelerator Applications SA – Key Employees 33
Advanced Accelerator Applications SA – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 36
Financial Announcements 36
Nov 17, 2017: Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 2017 36
Aug 31, 2017: Advanced Accelerator Applications Reports 32% Sales Growth for Second Quarter 2017 37
May 31, 2017: Advanced Accelerator Applications Reports 21% Sales Growth for First Quarter 2017 39
Mar 23, 2017: Advanced Accelerator Applications Reports 23% Sales Growth for Fiscal 2016; Continued NETSPOT Launch Success 41
Nov 28, 2016: Advanced Accelerator Applications Reports 15.4% Sales Growth in the Third Quarter of 2016 43
Aug 31, 2016: Advanced Accelerator Applications Reports 24.4% Sales Growth in the Second Quarter of 2016 44
May 31, 2016: Advanced Accelerator Applications Reports 29.6% Sales Growth in the First Quarter of 2016 45
Apr 29, 2016: Advanced Accelerator Applications reports 26.8% sales growth in 2015 and continues to show significant clinical progress across both therapeutic and diagnostic platforms 47
Corporate Communications 48
May 25, 2017: Advanced Accelerator Applications Appoints Christine Mikail to Board of Directors 48
May 26, 2016: Advanced Accelerator Applications Appoints Francois Nader, M.D., to Board of Directors 49
Product News 50
06/07/2016: Advanced Accelerator Applications Announces Expansion of Theranostic Pipeline with NeoBOMB1 50
Other Significant Developments 51
Jan 09, 2017: Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera NDA 51
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Advanced Accelerator Applications SA, Deals By Therapy Area, 2011 to YTD 2017 9
Advanced Accelerator Applications SA, Medical Devices Deals, 2011 to YTD 2017 10
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Advanced Accelerator Acquires Rights To Fabovar From Dompe 13
Advanced Accelerator Applications Raises USD26 Million in Venture Financing 14
Advanced Accelerator Applications Raises US$56 Million In Venture Financing 15
Advanced Accelerator Raises US$6 Million In First Tranche Of Venture Financing 16
Advanced Accelerator Secures US$57 Million In Venture Financing 17
Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 18
Vect-Horus Enters into Collaboration Agreement with Advanced Accelerator Applications for Radio-Imaging Agents 19
Advanced Accelerator Applications Enters into Licensing Agreement with Erasmus University Medical Center and Demokritos National Center 20
Advanced Accelerator Applications Enters into Licensing Agreement with Johns Hopkins University 21
Fujifilm RI Pharma Enters into Licensing Agreement with Advanced Accelerator Applications 22
Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 23
Advanced Accelerator Applications to Raise up to USD80 Million in IPO 25
Novartis to Acquire Advanced Accelerator Applications for USD3.9 Billion 27
Advanced Accelerator Applications Acquires IDB Group 29
Advanced Accelerator Applications Acquires Remaining 49.9% Stake in Atreus Pharma 30
Ion Beam Applications Acquires 25% Stake In PET Net 31
Advanced Accelerator Applications SA, Key Competitors 32
Advanced Accelerator Applications SA, Key Employees 33
Advanced Accelerator Applications SA, Subsidiaries 34

★海外企業調査レポート[Advanced Accelerator Applications SA (AAAP)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cardiff University:製薬・医療:M&Aディール及び事業提携情報
    Summary Cardiff University is an educational institution that offers education and research services. The institute provides undergraduate courses, post graduate courses, international courses, accommodations and libraries. It conducts research in the areas of engineering and physical sciences, bio- …
  • Astellas Pharma Inc.:企業のM&A・事業提携・投資動向
    Astellas Pharma Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Astellas Pharma Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Hsh Nordbank Private Banking:企業の戦略・SWOT・財務分析
    Hsh Nordbank Private Banking - Strategy, SWOT and Corporate Finance Report Summary Hsh Nordbank Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • GIZEH Raucherbedarf GmbH:企業の戦略的SWOT分析
    GIZEH Raucherbedarf GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Hotel Excelsior d.d.:企業の戦略・SWOT・財務分析
    Hotel Excelsior d.d. - Strategy, SWOT and Corporate Finance Report Summary Hotel Excelsior d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Precision Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Precision Biosciences Inc (Precision BioSciences) is a biotechnology company, which develops and commercializes gene therapy and cancer immunotherapy. The company focuses its ARCUS technology, a proprietary genome editing platform, which combines specificity and efficacy, on the development …
  • Japan Airlines Co Ltd:戦略・SWOT・企業財務分析
    Japan Airlines Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Japan Airlines Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • NanoString Technologies Inc (NSTG):企業の財務・戦略的SWOT分析
    Summary NanoString Technologies Inc (NanoString) is a developer of life science tools for translational research and molecular diagnostics. The company offers products such as sprint profiler, Dx analysis system with flex, nCounter MAX analysis system, protein assays, solid tumor assays, gene fusion …
  • Depomed, Inc.:企業の戦略・SWOT・財務情報
    Depomed, Inc. - Strategy, SWOT and Corporate Finance Report Summary Depomed, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • North Central Electric Cooperative, Inc.:発電所・企業SWOT分析
    North Central Electric Cooperative, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informa …
  • Lockheed Martin Aeronautics Company:企業の戦略・SWOT・財務分析
    Lockheed Martin Aeronautics Company - Strategy, SWOT and Corporate Finance Report Summary Lockheed Martin Aeronautics Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • InMed Pharmaceuticals Inc (IN):製薬・医療:M&Aディール及び事業提携情報
    Summary InMed Pharmaceuticals Inc (InMed), formerly Cannabis Technologies Inc, is a pre-clinical stage biopharmaceutical company which develops, produces and markets plant cannabinoid based medicines. The company's pipeline products include INM-750, INM-405, and INM-085. Its products finds applicati …
  • Novartis Institutes for BioMedical Research Inc-製薬・医療分野:企業M&A・提携分析
    Summary Novartis Institutes for BioMedical Research Inc (NIBR), a subsidiary of Novartis AG is a medical research institute that offers treatment research and development programs. The institute offers clinical research services in areas of immuno-oncology, oncology, neuroscience, cardiovascular and …
  • Recruit Holdings Co., Ltd.:企業の戦略・SWOT・財務情報
    Recruit Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Recruit Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Avarga Ltd:企業の戦略・SWOT・財務情報
    Avarga Ltd - Strategy, SWOT and Corporate Finance Report Summary Avarga Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Visiomed Group SA (ALVMG):医療機器:M&Aディール及び事業提携情報
    Summary Visiomed Group SA (Visiomed) is a medical device company. The company develops and distributes electronic medical devices. It offers screening and diagnosis products, pain relief products, prevention and treatment products, hearing and optics, family hygiene, children’s optics, baby bottle t …
  • Small Industries Development Bank of India:企業のM&A・事業提携・投資動向
    Small Industries Development Bank of India - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Small Industries Development Bank of India Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detai …
  • Brunswick Corporation:企業の戦略・SWOT・財務情報
    Brunswick Corporation - Strategy, SWOT and Corporate Finance Report Summary Brunswick Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Physiomics Plc (PYC):製薬・医療:M&Aディール及び事業提携情報
    Summary Physiomics plc (Physiomics) is a computational systems biology services company. It offers Virtual Tumour, which optimizes the dosing and scheduling of oncology drugs in pre-clinical trials, cardiac toxicity services through its EasyAP, a Web-based simulation and analysis tool. It also offer …
  • Mediobanca Banca di Credito Finanziario S.p.A.:企業の戦略・SWOT・財務分析
    Mediobanca Banca di Credito Finanziario S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Mediobanca Banca di Credito Finanziario S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆